Are currently receiving Abiraterone, Enzalutamide, Apalutamide or Darolutamide
Long-term retention is planned (intending to remain on the above stated treatments for at least the next 6 months).
You may not be if
Patients who are currently classed as in active treatment i.e. are currently receiving chemotherapy/radiation therapy (Note: Patients that are included in the study but after inclusion are moved onto chemo/radiation therapy, will still be able to participate in the project).
Patients who are stratified as high risk for having a cardiovascular event.
Acute illness; or any musculoskeletal, cardiovascular or neurological disorder that could inhibit or put them at risk from exercising, as determined by screening and their clinician.
